ASBRM: Drug Curbs Metastasis to Bone in Animal Model

Experimental drug targets a variety of enzymes thought to play role in metastasis

MONDAY, Sept. 25 (HealthDay News) -- An experimental drug known as ZK 304709 can prevent the metastasis of breast cancer cells to bone, and curb established breast cancer growth in bone in an animal model, according to data presented at the 28th annual meeting of the American Society for Bone and Mineral Research in Philadelphia. The oral drug, known as a multi-target tumor growth inhibitor, blocks a number of serine/threonine kinases and tyrosine kinases thought to play a role in metastasis.

Sanna-Maria Kakonen, Ph.D., and colleagues at Corporate Research Oncology at Schering AG in Berlin, Germany, evaluated oral doses of ZK 304709 in female mice injected with human breast cancer cells in a preventive trial and a therapeutic trial.

The preventive study lasted 22 days, with treatment beginning the day breast cancer cells were injected. The nine-day therapeutic study treated tumors already present in bone. The inhibitory compound prevented breast cancer from metastasizing to bone and stopped the growth of breast cancer that had metastasized to bone. The compound also reduced bone destruction caused by tumor growth, they reported.

"This study is of significance because this drug may ultimately prove useful in inhibiting the spread of breast cancer to bone," said Steve Goldring, M.D., the ASBRM president-elect, in a statement.

Abstract

Physician's Briefing